Last reviewed · How we verify
MK0249
At a glance
| Generic name | MK0249 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate the Effects of MK-0249 and an Alzheimer's Disease Medication on Cognitive Function in Adults With Alzheimer's Disease (MK-0249-023) (PHASE1)
- MK0249 for the Treatment of Cognitive Impairment in Patients With Schizophrenia (0249-016) (PHASE2)
- A Study to Test the Safety and Efficacy of MK0249 in Patients With ADHD (0249-018)(COMPLETED) (PHASE2)
- Treatment of Refractory Excessive Daytime Sleepiness in Patients With Obstructive Sleep Apnea/Hypopnea Syndrome (OSA/HS) Using Nasal Continuous Positive Airway Pressure (nCPAP) Therapy (0249-015) (PHASE2)
- MK0249 for the Symptomatic Treatment of Alzheimer's Disease (MK0249-011) (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MK0249 CI brief — competitive landscape report
- MK0249 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI